Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
1. Elanco's CPMA is the only USDA-approved treatment for canine parvovirus. 2. CPMA boasts a 93% survival rate, reducing hospital stays by nearly two days. 3. ParvoTrack tool helps track outbreaks, indicating a growing need for CPMA. 4. Texas and other states see high parvovirus cases, emphasizing CPMA's importance. 5. Elanco aims to save 1 million puppies from parvovirus by 2030.